ETFB

Across TCGA pan-cancer cohorts, ETFB mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ETFB data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ETFB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ETFB expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where ETFB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
LUAD	OS	Tertile	All	1.000	0.964	.043	4	view →
CCRCC	DFS	Median	III,IV	1.000	0.451	.032	2	view →
HNSC	DFS	Quartile	All	0.493	0.717	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ETFB–PDAC (DFS)

Open the PDAC breakdown →